

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	9 November 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 1. Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) 2. Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) 3. Alexandra Elizabeth Yatomi-Clarke
Date of change	18 December 2018
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 3,245,000 Fully paid ordinary shares 2. 976,912 Fully paid ordinary shares 3. 172,500 Fully paid ordinary shares
Class	Unlisted options exercisable at \$0.1021 (10.21 cents) per option, expiring on 18 December 2022

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	2,000,000
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	<p>Direct 2,000,000 Unlisted Options exercisable at \$0.1021 (10.21 cents) per option, expiring 18 December 2022</p> <p>Indirect</p> <ol style="list-style-type: none"> 1. 3,245,000 Fully paid ordinary shares 2. 976,912 Fully paid ordinary shares 3. 172,500 Fully paid ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued pursuant to Resolution 4 of the Company's 2018 Notice of Annual General Meeting approved by Shareholders on 20 November 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.